Gabriella Gobbi
Associate Professor
Psychiatry
McGill University
Canada
Biography
Dr Gobbi’s laboratory is interested in understanding the causes of mental diseases and in the discovery of new treatments for them. In particular, her laboratory is studying the short- and long-term effects of cannabis use in mood and anxiety and the potential beneficial effects of the drugs acting on the endocannabinoid system (endogenous cannabis) in the cure of mental diseases. Her laboratory is also studying the effect of melatonin in mood, anxiety, and sleep regulation in an effort to understand how novel selective ligands for melatonin receptors (called MT1 and MT2 receptors ) can be used to treat seasonal depression, major depression, sleep disorders, and other neuropsychiatric conditions. The laboratory approach spans from bench to bedside, bridging the gaps between the fundamental and clinical research. The techniques employed in the laboratory include in vivo electrophysiology, behavioural pharmacology, and neurochemistry. Dr Gobbi is also a psychiatrist in the Mood Disorders Program at the McGill University Health Centre. Her other interests include the psychopharmacology of violent behaviour and the neurobiological consequences of paternal separation.
Research Interest
mood disorders, depression, bipolar disorders
Publications
-
Practitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder. Atkin T, Nuñez N, Gobbi G
-
Serotonin transporter gene promoter methylation in peripheral cells in healthy adults: Neural correlates and tissue specificity. Ismaylova E, Di Sante J, Szyf M, Nemoda Z, Yu WJ, Pomares FB, Turecki G, Gobbi G, Vitaro F, Tremblay RE, Booij L
-
Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression. Gobbi G, Ghabrash MF, Nuñez N, Tabaka J, Di Sante J, Saint-Laurent M, Vida S, Kolivakis T, Low N, Cervantes P, Booij L, Comai S.